We do the sorting. You do the medicine.
Cardiac03 / 22

AF on apixaban for bleeding bladder tumour81-year-old man, 76 kg, with a bleeding bladder tumour for time-sensitive endoscopic resection

From memory: the diagnosis and the notes are hidden. Answer each question aloud, then press Show.

Know this first

  • CHA2DS2-VASc doubles points for age 75 or more and for prior stroke.
  • No bridging for a DOAC; interrupt by time instead.
  • Factor Xa inhibitors: at least 3 days off for minimal effect; ASRA asks 72 h before neuraxial block.
  • Reversal: andexanet alfa for apixaban, or prothrombin complex concentrate.

The patient

81-year-old man, 76 kg, with a bleeding bladder tumour for time-sensitive endoscopic resection, listed for tomorrow. Permanent AF, rate-controlled; stroke 2 years ago; hypertension; creatinine clearance 40 mL/min; climbs two flights slowly. Drugs: apixaban (last dose 30 hours ago), bisoprolol, amlodipine. Vitals: BP 132/78, HR 84 irregular, SpO2 95%, RR 16. Hb 10.1 g/dL.

The examiner asks

Answer aloud, then press Show.

  1. Consider

    What matters in this man?

    Show the answerHide the answer
    • An 81-year-old on apixaban with a past stroke, for time-sensitive resection of a bleeding bladder tumour. Patient
    • At 81, after a stroke and with clearance 40, his delirium risk is high; I screen cognition first.
    • Urgency: time-sensitive, so tomorrow's slot gives time to assess, not to delay. Stem trigger
    • Active cardiac conditions? None: his AF is rate-controlled at 84 and he isn't in failure. Disease
    • Risk score: his stroke is his only RCRI item; this isn't intraperitoneal surgery. RCRI 1.
    • Functional capacity: two flights of stairs, slowly, so over 4 METs.
    • Decision: RCRI 1, so no further cardiac tests; the real decision is his anticoagulation.
  2. Prepare

    How will you manage his anticoagulation?

    Show the answerHide the answer
    • His CHA2DS2-VASc is 5: age and stroke count double, plus hypertension. Disease
    • Bleeding risk is high too: active haematuria, age and reduced kidney function.
    • No heparin bridge; in AF it adds bleeding without stroke benefit.
    • Thirty hours since apixaban: anti-Xa or apixaban level; nothing measurable means no reversal.
    • Continue bisoprolol so his rate stays controlled through the hospital stay.
    • Agree timing and a restart plan with urology and his cardiologist beforehand.
    • Crossmatch, and have PCC and tranexamic acid ready in theatre. Crisis
  3. Plan

    Spinal or general anaesthesia?

    Show the answerHide the answer
    • Spinal is out; apixaban needs at least 72 hours off before a neuraxial block. Disease
    • General anaesthesia; induction with reduced propofol, under 1.5 mg/kg, for his age.
    • Lateral wall tumour: full relaxation stops the obturator jerk; an obturator block is deep, so also 72 hours. Surgery
    • Keep his pressure near baseline given his stroke history. Disease
    • Apixaban restarts 48–72 hours after this high-bleeding-risk procedure, once urine clears. After surgery
  4. Crisis

    During resection the irrigant turns frankly bloody; BP 84/50, HR 118, Hb 7.2 g/dL. What do you do?

    Show the answerHide the answer
    • Massive haemorrhage: frank bleeding, BP 84/50, HR 118, Hb 7.2, in an 81-year-old on apixaban. Crisis
    • Call for help; urology controls the bleeding point; massive transfusion protocol activated.
    • Two large-bore lines; red cells, plasma and platelets close to 1:1:1, all warmed.
    • Tranexamic acid: 1 g IV, given over 10 minutes.
    • His apixaban branch: andexanet alfa if stocked, otherwise four-factor PCC.
    • Ionised calcium checked as citrated blood runs; keep him warm and correct acidosis.
    • HDU afterwards; anticoagulation restarts jointly with urology and cardiology. After surgery

Fatal mistakes

  • Spinal anaesthesia within 72 hours of his last apixaban.
  • No reversal plan once bleeding threatens life.
  • Stopping his beta-blocker abruptly.
  • Bridging his apixaban with heparin.

Checked against: AHA/ACC 2024 · Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA Pain Medicine evidence-based guidelines (fifth edition) (2025) · Barash 9e · Stoelting 8e · Miller 10e

Report a problem with this case

Mark Got it only if you said every point. Again brings the case back tomorrow; Got it brings it back in 3, then 7, 14 and 30 days.

All Cardiac casesBack to today